Message #1 From:
Jason Date: March 17, 2007 08:29:32 AM
GNBT: Generex Biotechnology Granted Patents in Canada and Europe
Company Expands Drug Delivery Platform Patent Portfolio in Canada and Europe
Generex Biotechnology Corporation (NASDAQ: GNBT stock market forum), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has expanded its patent coverage with newly issued patents in Canada and Europe issued by the Canadian Intellectual Property Office and the European Patent office, respectively.
The Canadian patent titled "Pharmaceuticals Solubilized in Aerosol Propellant" relates to a formulation with a pharmaceutical agent solubilized in a propellant which can be administered buccally or into the lungs using a metered dose spray applicator.
The European patent titled "Pulmonary Drug Delivery" relates to an improved delivery system for the administration of large-molecule pharmaceuticals such as peptidic drugs, vaccines, and hormones, which may be administered by means of an aerosol into the mouth for buccal or pulmonary applications. The patent will take effect in several European countries including Germany, France, and the United Kingdom.
The Company currently holds an aggregate of 82 patents worldwide (20 of which are United States Patents) and has an aggregate of 60 patent applications pending in various jurisdictions.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.
